Condition: Colorectal Cancer · Epithelial Ovarian Cancer · Gastric Cancer · Sponsor: Blue Earth Diagnostics
This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
This description comes directly from the study's public registry record.
Jamie MacKay, MD, PhD · +447350456887 · jamie.mackay@blueearthdx.com
Evgenia Perkins · +19139576499 · evgenia.perkins@blueearthdx.com
Always discuss trial participation with your own doctor first.
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07432633